Galectin Therapeutics, Inc. announced that it will present top-line results from the NAVIGATE trial regarding its drug belapectin for patients with MASH cirrhosis and portal hypertension at the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback